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Schistosomiasis Epidemiology and Control:  How Did We
Get Here and Where Should We Go?
RF Sturrock
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel
Street, London WC1E 7HT, UK
Although a disease of great antiquity, scientific studies of schistosomiasis began only 150 years
ago.  The complete life-cycle was not described until just before the First World War,  making it possible
at last to plan proper community control programmes. Inadequate tools prevented their effective imple-
mentation until well after the Second World War when new tools became available, thanks to the newly
formed World Health Organization.   Molluscicides spearheaded control programmes until the late
1970s but were then replaced by the newly developed, safe drugs still used today. Whatever the method
used, the initial goal of eradication was, in the light of experience and cost, gradually replaced by less
ambitious targets;  first to stop transmission and then to reduce morbidity.  The most successful
programmes combined several methods to minimise reinfection after chemotherapy.  Comparisons be-
tween different programmes are difficult without using appropriate, standardised diagnostic tech-
niques and the correct epidemiological measurements. Some examples will be presented, mainly from
our studies on Schistosoma mansoni in Kenya.
Drug resistance on a scale comparable with malaria has not occurred in schistosomiasis but the
likely withdrawal of all drugs except praziquantel leaves its control extremely vulnerable to this
potential problem.  An effective, affordable vaccine for use in endemic countries is unlikely to be ready
for at least 5 years, and developing strategies for its use could take a further decade or more, judging
from experience with drugs and molluscicides.   In the interim, by analogy with malaria, the most cost-
effective approach would the use of drugs combined with other methods to stop transmission, including
molluscicides. The cost of molluscicides needs to be reduced and fears allayed about their supposedly
adverse ecological effects.
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(What follows is a an idiosyncratic view based
on nearly 40 years experience of schistosomiasis
research and control.  The views are my own but I
am indebted to those acknowledged below for un-
published Kenyan data used I have used in ex-
amples.)
Schistosomiasis is an ancient disease of man:
eggs have been recovered from Egyptian and Chi-
nese mummies several thousand years old (Nunn
& Tapp 2000). However, scientific studies of the
disease did not start until the middle of the 19th
century with independent reports, first by Japa-
nese workers, who described the early, acute
Katayama syndrome (Fuji 1847) and then by Bilharz
(1852) who found distome trematodes in the uro-
genital blood vessels during post mortem examina-
E-mail: sturrock@tesco.net
Received 14 May 2001
Accepted 25 July 2001
tions of Egyptian corpses. Over 60 years later, just
before the First World War, Japanese workers
(Miyairi & Suzuki  1914) finally incriminated am-
phibious, prosobranch snails of the genus On-
comelania as the intermediate host of the Oriental
schistosome, Schistosoma japonicum, and Leiper
(1915) showed that aquatic, pulmonate snails of
the genera Bulinus and Biomphalaria  transmitted
S. haematobium and S. mansoni, respectively.
Thus, the taxonomical problems about the genus
Biomphalaria, that have so exercised Dr Lobato
Paraense, were created by 19th century shell col-
lectors and naturalists ignorant of its medical im-
portance!
With the full description of the schistosome life-
cycle, public health workers could at last contem-
plate community control programmes.  It is, though,
one thing to speculate on theoretical control mea-
sures to eradicate snails from water bodies or worms
from people;  to prevent either contamination of
aquatic snail habitats by egg infested human ex-
creta or human exposure to cercarial infested
water;  or even to develop a vaccine to stop
schistosomula invading people (and all these ap-
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proaches were suggested at the time by ‘arm-chair
experts’!).  Putting them into practice is quite an-
other matter.  To ensure the success of any inter-
vention  requires the means, the funds and the will,
as well as sufficient knowledge of all aspects of the
schistosome transmission cycle.
EARLY CONTROL PROGRAMS AND THEIR
LIMITATIONS
In the initial absence of any antischistosomal
drugs, early control efforts focussed on the elimi-
nation of snails. Periodic drying of Egyptian irriga-
tion canals merely duplicated catastrophes which
snails were already used to in their natural habi-
tats.   Snail numbers dropped briefly but the survi-
vors soon replaced any losses.  Transmission was,
at best, merely interrupted.  Chemical control was
hampered because the water to be treated was that
used by people for domestic and agricultural pur-
poses.  Copper sulphate was the only ‘safe’ chemi-
cal readily available.  Highly effective in the labora-
tory, it was far less effective in the field, but re-
mained in use well into the 1950s.
Educating rural populations to prevent human
contamination of, and exposure to, potential trans-
mission sites has little chance of success without
provision of safe water supplies and acceptable
means of excreta disposal.  It was rapidly concluded
in Egypt that such provisions and their maintenance
would be impossibly expensive in rural areas.  This
remains the situation, today, in countries with en-
demic schistosomiasis (apart from the very few
which have achieved political and economic stabil-
ity so that everyone can afford to improve their
living conditions). Greater progress was possible
in stable urban centres where such measures were
cost effective and had many other potential ben-
efits.
At the end of the First World War, the chance
discovery of the antischistosomal properties of
Tartar Emetic against all three major schistosomes
infecting humans raised hopes of therapeutic in-
terventions using antimonial drugs (McDonagh
1918,  Christopherson 1918).  Long courses of pain-
ful injections and serious side effects meant that
they were really suitable only for treating patients
in hospital.  When used in the 1920s for outpa-
tients to try to prevent Egyptian labourers intro-
ducing S. haematobium  during the construction
of the new Sudanese irrigation schemes, mortality
was estimated at 3 per 1,000 patients treated (Jor-
dan 2000).
Between the two World Wars, community con-
trol of schistosomiasis was attempted in various
places based mainly on the combined use of the
two imperfect weapons available:  copper sulphate
and antimonial drugs, supplemented in some cases
by provision of safe water and sanitation.  Occa-
sional successes were claimed in Egypt but follow-
up studies showed them to be ephemeral as, for
example, at the Dakhla Oasis (Khalil 1938).  Far from
decreasing, the number of people exposed to schis-
tosomiasis was, if anything, increasing. Its distri-
bution was spreading as the number of habitats
available for the intermediate hosts was extended
by water development projects such as dams, irri-
gation schemes, river navigation improvements and
impedance of drainage associated with the grow-
ing construction of roads.
DEVELOPMENT OF CONTROL AFTER WORLD
WAR TWO
The World Health Organisation, formed after
the Second World War in 1948, found schistoso-
miasis control was little changed from that prevail-
ing at the end of the First World War.  Moreover,  it
promised to get worse when ambitious plans for
water resource developments were eventually ex-
ecuted to increase the agricultural and industrial
productivity of developing countries.  These de-
velopments, besides extending the number and dis-
tribution of potential snail habitats, resulted in mass
population movements and changed agricultural
practices, all favouring the spread of schistoso-
miasis.  At the time, few anticipated the human popu-
lation explosion in the second half of the century
which would greatly increase the number of people
at risk.  Accelerating migration from the country-
side to the town threatened to overwhelm existing,
aging water and sanitation systems, and to increase
urban schistosomiasis in the periurban slums.
Compared with malaria, which WHO confidently
(if, with hindsight, misguidedly) expected to eradi-
cate quite easily because of the range of effective
drugs and insecticides available, the schistosomia-
sis situation was very bleak. The main tools were
toxic antimonial drugs and an ineffective mollusci-
cide.  WHO orchestrated a research programme
by national, international and commercial
organisations to remedy the lack of molluscicides
and drugs.
Snail control
The first fruits of the WHO programme were
molluscicides which became available in the mid
1950s and one of which, niclosamide, is still in use
and effective today.  For the next  25 years, commu-
nity control of schistosomiasis was spearheaded
by molluscicides in Africa, south west Asia and, to
a lesser extent, the New World.  Careful biological
studies suggested an alternative approach to the
control of Oriental schistosomiasis:  Oncomelania
populations are less resilient than Biomphalaria
and Bulinus  spp. to disturbance.  Habitat modifi-
cation was recommended as a potential control
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measure because it also improved rice production
and this could, potentially, fund the elimination of
snail habitats (Pesigan et al. 1958).
Initial hopes of eradicating aquatic snails with
one or two molluscicide applications, especially
from irrigation schemes, were soon dashed.  Field
studies on snail population dynamics were under-
taken to improve the timing and efficacy of mollus-
cicidal applications (Dazo et al. 1966) and were fol-
lowed by field studies on transmission of the schis-
tosomes.  The seasonality of transmission was re-
vealed in many, though not all, areas.  Carefully
timed mollusciciding was then able to minimise, if
not stop, transmission in many places well into the
1980s (Sturrock et al. 1974).  However, the effect on
the human worm burden was slow (Jordan 1985).
Interest in molluscicides began to wane when new
drugs finally appeared and their decline was has-
tened by the sharp rise in the price of pesticides
after the oil crisis in the 1970s, and by a growing
(though largely unjustified) fear of adverse envi-
ronmental effects.  In some places they were com-
pletely abandoned.
Drug control
Development of drugs took much longer than
that of molluscicides.  By the early 1970s,
metrifonate was established for use against S.
haematobium, although the need for three fort-
nightly treatments caused logistic problems for
community use.  Fears for its safety prevented the
widespread acceptance of hycanthone, the first
single-dose drug effective against  S. mansoni  and,
possibly, S. haematobium, but a similar drug,
oxaminiquine, was released for community use
against S. mansoni in the 1970s. The real turning
point was the arrival in the early 1980s of
praziquantel, a safe, effective, single-dose drug
active for all schistosomes and many other human
and veterinary helminths, besides (WHO 1985). It
promised to revolutionise community chemo-
therapy against schistosomiasis, although it was
initially too expensive for widespread use. Its price
has at last dropped radically and it is now the major
weapon for community control of schistosomiasis.
New drugs revived hopes of eradicating schis-
tosomes directly by treating people.   Single-dose
treatment programmes certainly had dramatic re-
sults, but transmission persisted and reinfection
invariably occurred.  Experience showed that re-
peated treatments were essential to maintain initial
gains. As long as praziquantel remained expensive,
eradication seemed impossible:  morbidity control
became a more realistic objective.  The most suc-
cessful control programmes have been those that
included some method of curbing transmission,
including mollusciciding, even at a reduced level
(Webbe & El Hak 1990).  Transmission control de-
lays reinfection and extends the period between
treatments, thereby reducing drug delivery costs.
DIAGNOSIS AND EPIDEMIOLOGY
Identifying human schistosome infections is
crucial at all stages of schistosome control
programmes, and for comparing control
programmes.  Diagnostic methods are the key to
such comparisons and, not surprisingly, a great
many tests have been developed over the years.
Complete standardisation will never be achieved
but, if comparisons are to be justified, the tech-
niques used must be clearly described and their
limitations appreciated. Some methods most com-
monly used are summarised below.
Parasitological diagnosis
Adult worms lie hidden in the blood system
and parasitological diagnosis is therefore indirect
evidence of their presence within a patient, relying
on the detection of eggs in urine or faecal samples.
It is, though, absolutely specific because an egg is
direct proof of infection.  (Some caution is needed
for atypical eggs, e.g., S. bovis  eggs in an infected
cow liver can pass through the human bowel to
give the spurious appearance of infection (Kinoti
& Mumo 1988).)  The techniques are relatively
simple and cheap but technicians require proper
training and access to a microscope.  The main limi-
tations are that the techniques are slow, labour in-
tensive and aesthetically unpleasant.
Today, the most widely used methods are the
Kato thick smear (Katz et al. 1972) and the Nuclepore
filtration techniques for faecal and urine examina-
tion, respectively (Feldmeier 1993).  A standard, 50
mg Kato thick smear has a detection threshold of
20 eggs per gram (epg) of faeces (1 egg per slide):
smaller, quick, Kato smears have higher thresholds
(e.g., 50 epg for a 20 mg smear smear).  Nuclepore
filtration is conventionally used to examine 10 ml of
urine collected between 11.00 and 14.00 h at the
peak of the diurnal egg count cycle.  There is con-
siderable day to day variation in egg counts, both
in urine and faecal samples and there is little point
trying to estimate absolute worm burden from egg
counts for an individual because there are so many
possible sources of variation.  However, classifica-
tion of egg counts from a community on a rela-
tively coarse scale will detect overall trends after a
control intervention:  in this context, egg counts
are a quantitative, or at least a semi-quantitative,
measurement of infection – a few eggs indicating a
few worms and a lot of eggs, a lot of worms.  The
main deficiency of egg counts is missing very light
infections at or below the threshold of detection.
For quantitative purposes, examining duplicate
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samples on three or more days increases the chance
of finding eggs, but at increased costs in time and
labour (Engels 1997).
Immunodiagnostic methods
Immunodiagnosis of schistosomiasis relies
mainly on antibodies to detect antigens and vice
versa. In some, though not all, instances, their lev-
els in man are more stable than those of egg counts.
Invasive skin tests have been abandoned and most
tests are now performed on serum or plasma
samples from finger prick or venous blood.  Even
these procedures are considered intrusive and at-
tention is turning to other body fluids such as urine,
milk, and saliva or other oral exudates (Garcia Santos
et al. 2000).
Antibody detection tests provide only indirect
proof of exposure because they are molecules pro-
duced by the host’s immune response to the para-
site. Prepatent and early infections may not have
stimulated a detectable antibody response, result-
ing in false negative tests if the wrong antigen is
used.  Positive tests do not necessarily denote an
active (living) infection. Antibody tests are also
prone to cross reactions with other infections (es-
pecially tissue dwelling parasites) which diminishes
their sensitivity (for detecting infected cases) and
specificity (for detecting normal, uninfected
people).  However, improved reagents provided by
molecular biological techniques have revived in-
terest in antibody detection, particularly for spe-
cific isotypes and sub-classes associated with dif-
ferent stages of infection.  Imperfect correlations
between antibody levels and egg counts may give
some evidence of the intensity of infection in com-
munities. Positive antibody tests are usually, at
best, qualitative evidence of past or present expo-
sure to infection.
Antigen tests, by definition, detect molecules
produced by the parasite and are therefore just as
much direct proof of infection as finding eggs.
Antigen levels are often significantly lower than
those of antibodies, but, theoretically, are directly
related to the number of worms present.   Continu-
ously improving techniques now allow detection
of very low antigen levels.  Levels tend to be more
stable than egg counts but the relationship between
egg counts and antigen levels is not always per-
fect. Although antigen tests often confirm sus-
pected light infections with sparse eggs, negative
antigen tests still occur in subjects passing eggs.
Despite claims to the contrary, egg counts remain
the gold standard for diagnosis (Hagan et al. 1998).
At first, both antibody and antigen tests re-
quired access to dedicated laboratories to process
samples.  Recently, simple dip-stick/card tests have
been developed for field use (Van Etten et al. 1994)
but none are available commercially and they will
have to be cheap enough for routine use.
Indirect diagnostic methods
The association of S. haematobium with
haematuria is well known, especially among chil-
dren before puberty, although it is not always pre-
dictable.   In endemic areas, visual inspection of
daily urine samples over 3- to 5-days can be a simple,
cheap way to detect most infections in schoolchil-
dren and is of use in control programmes, with or
without the additional refinement (and cost) of dip-
sticks to detect blood and/or protein in the urine
(Savioli et al.  1990).  The association of signs and
symptoms is less clear cut for S. mansoni and S.
japonicum:  other causes must be ruled out,  espe-
cially for diarrhoea and bloody diarrhoea.
Hepatosplenomegaly and splenomegaly, detected
clinically by palpation, often occur in high trans-
mission endemic areas, and indicate significant
schistosomal pathology.   Subjective, between-ob-
server variations in these clinical measurement re-
main a problem despite attempts at standardisation
using defined axes for reporting results (Doehring-
Schwerdtfeger et al. 1995).
The development  in the last 10 to 15 years of
portable ultrasound equipment suitable for field use
has been a significant advance (Hatz 1993).  The
equipment is not cheap, properly trained operators
are required and the technique does not detect
worms or eggs directly.  Its main contribution is the
accurate measurement of various organs and in the
visualisation of lesions characteristic of schisto-
somiasis in either the hepatic portal plexus, includ-
ing the liver and spleen, or the urogenital system.
There remain, though, problems in interpreting
the results from different areas. Suggested
standardised measurements have not proved uni-
versally applicable, hampering comparisons of be-
tween areas.  Ultrasound is, nevertheless, useful in
characterising the clinical situation within areas and,
potentially, for monitoring the effects of control
interventions.
EPIDEMIOLOGICAL MEASUREMENTS IN SCHIS-
TOSOMIASIS
Commonly used measurements
The human measurements most widely used in
schistosomiasis epidemiology are based on the
prevalence of active infections in the community.
Prevalence classifies subjects as positive or nega-
tive for (usually) the presence of eggs, and is re-
corded as the proportion or percentage positive.
Cure rate (CR) is the percentage of patients who
stop passing eggs within 5 or 6 weeks after treat-
ment). Incidence records changes from negative to
positive over a predetermined time period.  All three
measurements are qualitative, binary variables and
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none  indicates the intensity of infections – an im-
portant consideration for long-lived, helminths
which do not multiply in the host and whose num-
bers increase only after repeated exposures over
time.
In contrast, intensity is a continuous, quantita-
tive variable expressed as epg for faeces or as eggs/
10 ml for urine.  Within a community, the individual
egg counts are distributed asymmetrically with most
of the eggs passed by 10%-20% of the subjects
and the rest passing few or no eggs.  Egg counts
are conventionally transformed to log(x+1) to in-
clude zero counts and normalise their distribution
for statistical analysis, but reported in epg as the
geometric mean (GM = antilog[{Σlog(x+1)}/n] - 1,
where n = the number of subjects in any age, sex,
age-sex or other group).  Despite their admitted
shortcomings, egg counts reflect the number of
worms present at a specific time.  They also show
significant changes when, for example, children
acquire increasing worm loads due to cumulative
exposure over time, or worm numbers drop after
successful treatment.  If egg counts are near the
threshold of egg detection, especially after treat-
ment, sufficient replicate samples must be exam-
ined to avoid misclassifying light infections as nega-
tive.
In practice, the easiest measurements to obtain
and the most widely used are the qualitative indi-
cators (prevalence, cure rate and annual incidence)
but they are relatively insensitive and reveal only
gross changes.  The most informative is annual
incidence (the rate of transmission in an accurately
defined cohort of uninfected subjects) although it
may be hard to obtain in high prevalence areas
where uninfected subjects may confined to atypi-
cal age groups such as very young children.  Quan-
titative measurements of intensity, though more
difficult to obtain, are more sensitive to change,
especially repeated measurements on a cohort.
Although fundamentally different measure-
ments, prevalence and intensity are related: preva-
lence rises with increasing intensity to an upper
limit of 100% but intensity has no theoretical upper
limit.  It is now accepted (WHO 1998) that rising
intensity is accompanied by an increased risk of
developing morbidity and disease (pathology of
the urogenital tract; hepatomegaly and hepatosple-
nomegaly). However, severe pathology can occur
in light infections and does not develop in all heavy
infections.
Planning control programmes
When snail control for schistosomiasis began
in earnest in the 1950s and 1960s, the tacit aim was
to eradicate the snails and hence, ultimately, the
parasites;  a process that might take one or more
decades. Only qualitative egg counting techniques
were available and success, if any, was judged pri-
marily by reductions in prevalence (and incidence)
of schistosomiasis in human populations. Twenty
years later, when effective drugs came into use, the
prevailing view was that they would succeed, where
molluscicides had failed, in eradicating schistoso-
miasis by attacking the parasites directly.  Assess-
ment was still based mostly on qualitative criteria
although quantitative egg counts were available
by then. Rapid and dramatic prevalence drops after
chemotherapy and quantitative measurements, if
used, confirmed that drugs had more rapid effects
than snail control (Cook et al. 1977).
Only gradually was it realised that it would be
no easier to eradicate worms than snails.  Just as
the goal of snail control had shifted from eradica-
tion to the management of snail populations to sup-
press transmission, so, too, did the goal of chemo-
therapy change;  from eradicating worms to sup-
pressing their numbers to a level where they would
no longer be of public health significance in the
population (WHO 1985).  Reducing the overall com-
munity worm burden should reduce the numbers
of heavily infected people likely to develop dis-
ease.
To select the most appropriate control strategy
for an area required some framework (WHO 1993).
One such was based on a combination of age-
prevalence and age-intensity curves (Fig. 1).  Al-
though there are differences in detail between the
different human schistosomes, a generalised pic-
ture shows that overall prevalence rises to a peak
in school children in the second decade of life be-
fore dropping to a somewhat lower level in older
age groups (Ross et al. 2000).  Plotting prevalence
prev
age
1 mass
2
3
4
+ve
heavy +ve
(easy) (hard)
Fig. 1: diagrammatic representation of schistosomiasis age-
prevalence curves to indicate various chemotherapy con-
trol strategies: 1. mass treatment of entire community
without diagnosis (thick broken slope); 2. treatment tar-
geted at all subjects diagnosed positive (upper thin-lined
curve);  3. selective treatment targeted at people diagnosed
as heavily infected (lower thick-lined curve;  and 4. selec-
tive treatment targeted at school children (vertical thick
broken lines) using 1, 2 or 3 as appropriate.
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of heavy infections (>400 epg or >1000 epg for in-
testinal schistosomiasis;  >50 or >200 eggs/10 ml
for urinary schistosomiasis) gives a similar curve
below that of total prevalence in each age group.
The proportion of heavy infections is greatest at,
or immediately after, the overall prevalence peak in
school children.  In older age groups, heavy infec-
tions are relatively lower than the total prevalence.
This figure suggests several control strategies.
The simplest  approach (Fig. 1.1) is mass che-
motherapy, treating everybody in a known, endemic
community with a curative dose of praziquantel.
This was impossible in most endemic areas, if only
because of the high cost of praziquantel at the time.
Alternatives included targeted chemotherapy  (Fig.
1.2), treating only infected subjects after examining
everyone in the community to diagnose those in-
fected;  selective, targeted chemotherapy (Fig. 1.3),
treating only those subjects with heavy infections
(also needing diagnosis); and selective, targeted
chemotherapy (Fig. 1.4), treating subjects in de-
fined, high-risk groups (e.g. school children), with
mass treatment (or targeted or selective, targeted
chemotherapy with diagnosis).
Other factors affect the choice of strategy in-
cluding the overall prevalence and intensity in a
community, the nature and accessibility of its mem-
bers, the proportion of the children who regularly
attend school, where transmission occurs and if it
is seasonal (and, if so, if it varies in intensity from
year to year).  At least one national programme
(Brazil) followed these principles (Almeida
Machado 1980).
Evaluation of control programmes
Snail control aimed to stop transmission.  It had
no immediate effect on the existing worm popula-
tion in people and cure rates were irrelevant be-
cause of the long life-span of adult schistosomes.
Overall prevalence remained unchanged for sev-
eral years until worms died.  A downward shift in
the elevation of age-prevalence curves confirmed
reduction in transmission and changes in the an-
nual incidence were a more sensitive, qualitative
indicator of success but took just as long to ob-
tain.  In contrast, repeated, quantitative measure-
ment of intensity revealed changes over a year or
even a single transmission season (Jordan 1985).
Qualitative incidence (where possible) and quanti-
tative measurements are appropriate for other mea-
sures for transmission control such as water sup-
plies, sanitation and public health education.
Drugs kill the adult schistosomes but even
praziquantel fails to kill every worm in every pa-
tient.  Anyone passing a single egg after treatment
is considered positive and, thus, a treatment fail-
ure, so the cure rate for a community is a poor mea-
sure of the effect of chemotherapy.  Nor is preva-
lence much better.  The percentage reduction (PR)
in GM egg output is much more sensitive. For epi-
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Fig. 2: age prevalence and intensity profiles from 1989 to 1992 (years 1 to 4) in two Kenyan communities: Kitengei,
where school children were treated annually after the 1989 survey for  Schistosoma mansoni; and Matathini, which
received no systematic treatment in this period. (Age groups 1-6 were:  0-4, 5-8, 9-12, 13-20, 21-40 and over 40 years
old respectively at start of study).
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demiological studies, the PR should be calculated
for ALL subjects, uninfected and infected, before
and after treatment.  It is sometimes calculated only
for patients who are not cured (Stelma et al. 1995).
This may be of clinical interest to assess the risk of
residual infections causing subsequent morbidity,
but it is not strictly an epidemiological measure-
ment reflecting events in the community as a whole.
EPIDEMIOLOGICAL MEASUREMENTS IN
SCHISTOSOMIASIS: EXAMPLES FROM KENYA
The following examples are drawn from a series
of studies on the control of S. mansoni in Kenya
over the last two decades to illustrate the use of
these epidemiological measurements and their were
interpretation.
Prevalence, intensity, cure rates and percentage
egg count reduction
Table I shows data from three different commu-
nities in the Machakos and Makueni Districts of
Kenya. Surveys in each community were performed
on 500 to 600 individuals who provided faecal
samples on three different days.  Two Kato smears
were examined from each sample (6 smears in total
for each individual).  All infected subjects were then
treated with praziquantel (40 mg/kg) and the effect
assessed three months later.  (A five or six week
follow up, before worms acquired after treatment
could have begun producing eggs, would have
been better but three months was used for logisti-
cal reasons).  Contemporary data from Senegal
(Stelma et al. 1995) are shown for comparison.
There was a direct correlation between pretreat-
ment prevalence and intensity. Both were inversely
related to cure rate (except the lowest Kenyan preva-
lence – a common discrepancy because the low
prevalences include more light infections likely to
be misclassified as normal, even with three faecal
samples).  Although the cure rates seemed disap-
pointingly low (41% at best), the reduction in egg
output (intensity) was over 80% in all cases.  The
Senegal result was an under estimate, based on
treatment failures alone, but was the evidence for
the ‘unexpected failure of praziquantel’ against S.
mansoni  (Anon 1992), raising fears of drug resis-
tance, subsequently allayed by retreatment stud-
ies (Picquet et al. 1998) and attributed to the high
infection intensities (De Vlas et al.1998).
Age-prevalence and age-intensity for monitoring
the effect of chemotherapy
Figure 2 shows data from two Kenyan commu-
nities from 1989 to 1992.  The first, Kitengei, was in
Makueni District (formerly part of Machakos Dis-
trict) about 200 km south east of Nairobi in an area
of intense S. mansoni transmission; the second,
Matathini, also in Machakos District about 100 km
east of Nairobi, was in an area of moderate trans-
mission.   Kitengei had received no systematic treat-
ment before late 1989 when annual treatment for
three years began for all school children found in-
fected at annual surveys.  At Matathini, all infected
subjects had been treated with praziquantel in 1988,
but received no further treatment until the study
ended and all infected subjects in both communi-
ties were offered treatment.
The Kitengei community before treatment had
a typical, convex, age-prevalence curve, peaking at
nearly 100% in the 13-20 year olds. The first treat-
ment markedly reduced prevalence  and initial gains
were maintained by the third treatment after a set
back in the second year. The effect was greatest in
children over 12 years of age though their preva-
lence still exceeded 50%.  Age-intensity profiles
revealed a more encouraging picture:  a <90% drop
achieved initially in all target groups was maintained
by subsequent treatments, despite a slight resur-
gence in the second year.  A 50% reduction in in-
tensity among untreated adults over the three year
period was an added bonus. Both prevalence and
intensity data suggest an especially intense trans-
mission season in year 2.
At Matathini, the atypical starting age preva-
lence and intensity curves reflect treatment in 1998.
The typical teenage prevalence peak was firmly re-
established within three years although intensity
TABLE I
Changes in prevalence and intensity of  Schistosoma mansoni in three Kenyan communities and a Senegalese
community after treatment with praziquantel
Pretreatment 3 months after treatment
 Group     n % prevalence   GM epg % cure rate  % egg reduction
Kenya 1 ~550   82.3%               32 20.7%           84%
Kenya 2 ~550   93.3%             198 40.6%           98%
Kenya 3 ~550   95.8%             440 18.7%          94%
Senegala   298 100%               713 18%            86%
a: Stelma et al. (1995)
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rose less rapidly.  Both prevalence and intensity
suggested especially intense transmission in the
second year, as at Kitengei.
Effect of chemotherapy on clinical morbidity
Repeated treatment at Kitengei successfully
reduced the intensity of S. mansoni infections in
the target groups, but did it affect morbidity?   Table
II summarises findings from a series of clinical sur-
veys performed at Kitengei during and after the
chemotherapy study.  At each survey, subjects
were examined by the same clinical observers in a
standardised manner for enlarged spleens and liv-
ers.  Epidemic malaria occurs in this area and the
convention used by Fulford et al. (1996) was
adopted to differentiate between its effect (sple-
nomegaly alone) and that of S. mansoni (hepatome-
galy and hepatosplenomegaly).
Splenomegaly was low (<6%) and steady until
a sharp rise in a malaria epidemic during the last
survey caused a significant rising trend over time.
In contrast, the prevalence of hepatomegaly and
hepatosplenomegaly declined steadily and signifi-
cantly during and beyond the treatment programme.
Annual praziquantel treatment had a beneficial ef-
fect on S. mansoni pathology, even though trans-
mission continued but severe cases remained,
though far less common than before.
Measurement and control of transmission in
snails in Kenya
Transmission of S. mansoni in the Machakos/
Makueni Districts of Kenya - So far, the Kenyan
examples have focussed on measuring the effect of
chemotherapy on S. mansoni  infections and their
clinical sequelae in people. Snails have been ig-
nored although they are essential for transmission.
In this part of Kenya, S. mansoni is transmitted by
B. pfeifferi, mainly in small streams and rivers where
human contact is considerable.  The snails origi-
nate from colonies in pools and marshy seepages
at the head waters of the Athi River.  In favourable
conditions, they spill into the tributaries, forming
colonies where snails become abundant and wide-
spread.  However, these colonies are washed com-
pletely away by heavy rains (Sturrock et al. 1994).
As rainfall is seasonal in Kenya, there are corre-
sponding  fluctuations in snail numbers within
years. There are also marked variations between
years related to annual rainfall.
Transmission studies related to the 1989-1992
praziquantel trial - Representative sites were
sampled fortnightly to monitor S. mansoni trans-
mission by B. pfeifferi.  Two crude indices were
used to compare areas for a given year;  the abun-
dance of snails and the S. mansoni  infection rate.
Abundance is the geometric mean number of snails
per sampling site per year. The infection rate is the
percentage of all snails collected shedding schis-
tosome cercariae.
At Kitengei, the abundance of B. pfeifferi  for
the four years from 1989 to 1992 was 689, 2573, 1826
and 653 snails per site, respectively. At Matathini,
the equivalent figures were  376, 259, 461 and 156.
Despite greater variability between years, snails
were four to five times more abundant at Kitengei.
The corresponding S. mansoni  infection rates were
1.3%, 5.7%, 8.6% and 1.5% at Kitengei, and 9.2%,
0.7%. 4.4% and 0.2% at Matathini, showing con-
sistently higher infection rates at Kitengei, apart
from 1989.
The snail and parasitological data both indi-
cate low transmission at Kitengei in years 1 after
chemotherapy began, increasing in year 2 and 3
when further treatments just about maintained the
reductions in prevalence and intensity achieved
during unusually low transmission in the first year.
Transmission at Matathini, although lower than at
Kitengei, was sufficient to allow steady reinfection
in the absence of chemotherapy.
Attempts to contain S. mansoni transmission -
We were interested in studying whether the regres-
sion in pathology indicated in Table II would con-
tinue in the absence of reinfection.  Studies such
as those already described showed that repeated
TABLE II
 Changes in prevalence of splenomegaly and combined hepatomegaly and hepatosplenomegaly  in a Kenyan
community during a programme of annual treatment of  Schistosoma mansoni  cases with praziquantel
Year n % normal % splenomegaly % hepatosplenomegaly
(malaria)       (S. mansoni)
1989 598     71.4%  3.8% 24.7%
1990a 557    79.5%  5.7% 14.8%
1990b 591    84.9%  3.6%  11.5%
1991 552    88.2%  2.4%   9.4%
1992 575 88%  5.2%     6.8%
1993  581    89.5%   5.5%  5%
1995 569    82.4% 14.1%    3.5%
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chemotherapy alone could prevent the more seri-
ous consequences of S. mansoni infection but re-
infection was inevitable if transmission continued.
Considerable information acquired by earlier stud-
ies (Sturrock et al. 1994) showed the instability of
stream snail colonies related to rainfall and, hence,
the seasonality of transmission.  We were already
routinely giving chemotherapy between transmis-
sion seasons to avoid rapid reinfection but pre-
dicting S. mansoni transmission is no more accu-
rate than weather forecasting.  Could we render
streams inimical to snails during transmission sea-
sons? Mollusciciding seemed to be the answer.
Regular surveillance was started to detect snails
invading streams cleared by the last rains.  Any
colonies found were treated focally with hand
sprayers to apply molluscicide (niclosamide) ac-
cording to the maker’s recommendation.  This ac-
tion gave good control until the critical period be-
fore the onset of the next rains when rising tem-
peratures and gentle flows favoured rapid growth
of aquatic flora, increased the number of potential
snail habitats and accelerated both the growth of
the snail colonies and the development of the S.
mansoni in the snails.  At such times, the entire
stream was treated with  8 mg.h.l-1  of niclosamide
from an upstream, continuous-flow dispenser,
supplemented by hand spraying of overgrown
stream margins to boost the chemical concentra-
tion in areas most favoured by snails.
Table III summarises snail records for six years
from two, adjacent tributaries of the Athi River,
Makueni District.  Mollusciciding of one stream
began in 1995.  Rainfall was measured near this
stream and varied considerably from year to year.
In the wettest (El Nino) year in 1997/1998, most of
the 1430 mm fell as widespread rainfall affecting
both tributaries between mid-December and mid-
January.  In other years, localised storms affected
one area more than the other, accounting for differ-
ences between the two areas before mollusciciding
began.  Thereafter, snail populations in the untreated
area were fairly stable except in the El Nino year
and S. mansoni infection rates were always in the
range of 1 to 3%.  In the treated area, mollusciciding
took time to have an effect but infected snails,
though occasionally found, were much scarcer than
in the untreated area.  More important, snails, in-
cluding infected snails, were confined to the upper
reaches of the stream, well away from the study
populations.  Human data have yet to be fully
analysed, but preliminary indications are that trans-
mission has been held to an extremely low level.
THE NEED FOR TRANSMISSION CONTROL
Our experience in Kenya is matched by similar
studies in Africa and elsewhere which all agree that
drugs alone, although they will have public health
benefits in reducing the pathological consequences
of infection, will not eliminate transmission of schis-
tosomiasis.   Retreatment is essential to maintain
initial reductions of prevalence and intensity.
The good news is that the price of praziquantel
has dropped sharply in recent years.  There has
been an epidemic of mass treatment campaigns but
these are mostly of short term,  even those incor-
porating retreatment.  The bad news is that these
programmes will not stop transmission:  when they
end, prevalence, intensity and, eventually, pathol-
ogy will rise again (Chen & Feng 1999). Decision
makers will, by then, be unwilling to spend more on
what they will perceive as an ineffective control
measure.  Worse still is that the alternative drugs,
metrifonate for S. haematobium and oxamniquine
for S. mansoni, are now effectively unobtainable
(Hagan et al. 2000) and we will be back to square
one if resistance to praziquantel ever becomes a
reality.  Worse still, commercial companies have
abandoned research on developing new drugs.
Like WHO 50 years ago, we would have no effec-
tive drug although there would still be an effective
molluscicide.
I must stress that I do not see molluscicides as
a universal panacea for schistosomiasis control.
Despite a recent revival of interest in plant mollus-
cicides there is little evidence that they can be pro-
duced in sufficient amounts for use in a routine
control programme of any size.   The only tried and
tested,commercially-produced molluscicide is
niclosamide. Of course, there are many situations
where its use is inappropriate. But why is it not
more widely used where it is appropriate?  An ob-
vious reason is its high cost.   For other tropical
parasites, international agencies have successfully
TABLE III
Snail data for six years from two tributaries of the Athi
River, Makueni District, Kenya before and after
introducing mollusciciding to suppress the
transmission of Schistosoma mansoni
        Mean no. of snails/site
      (% S. mansoni +ve)
Year Rainfall Treated area Untreated area
  (mm)       (17 sites)    (10 sites)
1993/94    536 2268   (4.1%) 387   (2.3%)
1994/95    850    25   (0.1%) 991   (2.8%)
(Start of mollusciciding)
1995/96    782 225     (2%)
1996/97    316  64   (0.4%) 702   (2.2%)
1997/98  1430    4      (0%) 282   (1.2%)
1998/99    569  67   (0.9%) 549   (2.8%)
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negotiated the provision of cheap or even free drugs
to countries which could not otherwise afford them.
Why not do the same for niclosamide?  A second
reason lies in fears that niclosamide is dangerous,
if not for man, then for the environment, despite
extensive evidence to the contrary (Webbe 1987).
If not molluscicides, what alternative means of
transmission control remain?  Provision of safe
water supplies and sanitation is a council of per-
fection beyond the financial resources of most
countries with endemic schistosomiasis.  Yet with-
out them, what hope has any public health educa-
tion campaign?  People can not change their
behaviour without the means of doing so.  Even if
these facilities were available, natural water bodies
in hot climates would remain magnets for children
to perpetuate schistosomiasis transmission.
There is one other hope – a vaccine to reduce
egg output if not to prevent infection.  For 30 years
I have repeatedly been told that there will be a one
within five years, a promise that has yet to be ful-
filled, though I am assured that things are chang-
ing. Even if a vaccine is successfully tested soon,
it will take many years to bring it into widespread
use and it will be no easier or cheaper than mollus-
cicides or drugs, judged by past experience.
What can we do in the interim?   There seems
little prospect of a dramatic upturn in the world
economy, sufficient to allow endemic countries to
raise the living standards of their people enough to
affect schistosomiasis transmission. It seems we
must rely on repeated praziquantel treatments, en-
suring that its quality is not sub standard and pray
that significant resistance does not develop (WHO
1998).   On which sombre note I will close!
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